One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial

Transplantation

Volumn 100, Issue 2, 2016, Pages 391-399

  Sautenet, Bénédicte ^a,b   Blancho, Gilles ^c   Büchler, Mathias ^a,b   Morelon, Emmanuel ^d   Toupance, Olivier ^e   Barrou, Benoit ^f   Ducloux, Didier ^g   Chatelet, Valérie ^h   Moulin, Bruno ⁱ   Freguin, Caroline ^j   Hazzan, Marc ^k   Lang, Philippe ^l   Legendre, Christophe ^m   Merville, Pierre ⁿ   Mourad, Georges ^o   Mousson, Christine ^p   Pouteil Noble, Claire ^q   Purgus, Raj ^r   Rerolle, Jean Philippe ^s   Sayegh, Johnny ^t   Westeel, Pierre François ^u   Zaoui, Philippe ^v   Boivin, Hedia ^a   Le Gouge, Amélie ^a   Lebranchu, Yvon ^a,b   more..

^a CHU BRETONNEAU   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e HÔPITAL MAISON BLANCHE   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^h CAEN UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^j ROUEN UNIVERSITY HOSPITAL   (France)

^k LILLE UNIVERSITY HOSPITAL   (France)

^l HENRI MONDOR HOSPITAL   (France)

^m HÔPITAL NECKER ENFANTS MALADES   (France)

ⁿ HÔPITAL PELLEGRIN   (France)

^o MONTPELLIER UNIVERSITY HOSPITAL   (France)

^p DIJON UNIVERSITY HOSPITAL   (France)

^q HOSPICES CIVILS DE LYON   (France)

^r ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^s LIMOGES UNIVERSITY HOSPITAL   (France)

^t ANGERS UNIVERSITY HOSPITAL   (France)

^u AMIENS UNIVERSITY HOSPITAL   (France)

^v GRENOBLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CORTICOSTEROID; CREATININE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PLACEBO; RITUXIMAB; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ADVERSE OUTCOME; ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; ARTICLE; BK VIRUS INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE ANALYSIS; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HEMATOLOGIC DISEASE; HERPES VIRUS INFECTION; HISTOPATHOLOGY; HUMAN; ILEITIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHATIC SYSTEM DISEASE; LYMPHOCYTE COUNT; MALE; MELANOMA; MULTICENTER STUDY; NOCARDIOSIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEPSIS; URINARY TRACT INFECTION; ACUTE DISEASE; ADVERSE EFFECTS; BIOPSY; BLOOD; CLINICAL TRIAL; CONVALESCENCE; DRUG EFFECTS; FRANCE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; IMMUNOLOGY; KIDNEY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; BIOMARKERS; BIOPSY; CREATININE; DOUBLE-BLIND METHOD; FEMALE; FRANCE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; RITUXIMAB; TIME FACTORS; TREATMENT OUTCOME;

EID: 84957431006     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000958     Document Type: Article

References (47)

1. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. NEngl J Med. 2010;363:1451-1462.
2. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8: 753-760.
3. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of BanffWorking Groups. Am J Transplant. 2010;10:464-471.
4. Solez K, Racusen LC. The Banff classification revisited. Kidney Int. 2013; 83:201-206.
5. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation. 1993;55:752-756; discussion 756-757.
6. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol. 1999;10: 167-181.
7. Monaco AP, Burke JF Jr, Ferguson RM, et al. Current thinking on chronic renal allograft rejection: Issues, concerns, and recommendations from a 1997 roundtable discussion. Am J Kidney Dis. 1999;33:150-160.
8. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve longterm outcomes after renal transplantation. N Engl J Med. 2002;346: 580-590.
9. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9:S1-S155.
10. Transplant-Commentary2010-AJKD.pdf (Objet application/pdf) [Internet]. [cited 2013 Feb 27]. Available at: http://www.kidney.org/professionals/kdoqi/pdf/Transplant-Commentary2010-AJKD.pdf.
11. TxpGL-publVersion.pdf (Objet application/pdf) [Internet]. [cited 2013 Feb 27]. Available at: http://www.kdigo.org/clinical-practice-guidelines/pdf/TxpGL-publVersion.pdf.
12. Roberts DM, Jiang SH, Chadban SJ. The Treatment of acute antibodymediated rejection in kidney transplant recipients-a systematic review. Transplantation. 2012;94:775-783.
13. Fehr T, Gaspert A. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl Int. 2012;25: 623-632.
14. Barnett AN, Hadjianastassiou VG, Mamode N. Rituximab in renal transplantation. Transpl Int. 2013;26:563-575.
15. Zarkhin V, Li L, Kambham N, et al. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. AmJ Transplant. 2008;8:2607-2617.
16. Lehnhardt A, Mengel M, Pape L, et al. Nodular B-cell aggregates associated with treatment refractory renal transplant rejection resolved by rituximab. Am J Transplant. 2006;6:847-851.
17. Moscoso-Solorzano GT, Baltar JM, Seco M, et al. Single dose of Rituximab plus plasmapheresis in an HIV patient with acute humoral kidney transplant rejection: a case report. Transplant Proc. 2007;39: 3460-3462.
18. Celik A, Saglam F, Cavdar C, et al. Successful therapy with rituximab of refractory acute humoral renal transplant rejection: a case report. Transplant Proc. 2008;40:302-304.
19. Alausa M, Almagro U, Siddiqi N, et al. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab. Clin Transplant. 2005;19:137-140.
20. Yang YW, LinWC,Wu MS, et al. Early diagnosis and successful treatment of acute antibody-mediated rejection of a renal transplant. Exp Clin Transplant. 2008;6:211-214.
21. Becker YT, Becker BN, Pirsch JD, et al. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant. 2004;4:996-1001.
22. Vega J, Goecke H, Carrasco A, et al. Rituximab in the treatment of acute cellular rejection of renal allograft with CD20-positive clusters in the infiltrate. Clin Exp Nephrol. 2011;15:308-311.
23. Tanriover B, Wright SE, Foster SV, et al. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis. Transplant Proc. 2008;40: 3393-3396.
24. Faguer S, Kamar N, Guilbeaud-Frugier C, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation. 2007;83:1277-1280.
25. Gomes AM, Pedroso S, Martins LS, et al. Diagnosis and treatment of acute humoral kidney allograft rejection. Transplant Proc. 2009; 41:855-858.
26. MulleyWR, Hudson FJ, Tait BD, et al. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation. 2009;87:286-289.
27. Rodríguez Ferrero M, Rincón A, Bucalo L, et al. Treatment of acute antibody-mediated rejection: a single-center experience. Transplant Proc. 2010;42:2848-2850.
28. Kaposztas Z, Podder H, Mauiyyedi S, et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant. 2009; 23:63-73.
29. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant. 2009;9:1099-1107.
30. Levey AS, Bosch JP, Lewis JB, et al. Amore accuratemethod to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann InternMed. 1999; 16(130):461-470.
31. Gill PS. A robust mixed linear model analysis for longitudinal data. Stat Med. 2000;19:975-987.
32. Woodle ES, Gebel HM. Regulatory approval for new antihumoral therapies: addressing the barriers. Am J Transplant. 2011;11:880-881.
33. Venetz JP, Pascual M. New treatments for acute humoral rejection of kidney allografts. Expert Opin Investig Drugs. 2007;16:625-633.
34. Ramos EJ, Pollinger HS, Stegall MD, et al. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant. 2007;7:402-407.
35. Kohei N, Hirai T, Omoto K, et al. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant. 2012;12:469-476.
36. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359:242-251.
37. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation. 2010;89:1095-1102.
38. Loupy A, Suberbielle-Boissel C, Zuber J, et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation. 2010;89:1403-1410.
39. Vo AA, Choi J, Cisneros K, et al. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation. 2014;15(98):312-319.
40. Vo AA, Sinha A, Haas M, et al. Factors predicting risk for antibodymediated rejection and graft loss in highly human leukocyte antigen sensitized patients transplanted after desensitization. Transplantation. 2015; 99:1423-1430.
41. Zachary AA, Lucas DP, Montgomery RA, et al. Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA. Transplantation. 2013;95:701-704.
42. Stegall MD, Chedid MF, Cornell LD. The role of complement in antibodymediated rejection in kidney transplantation. Nat Rev Nephrol. 2012;8: 670-678.
43. Gaughan A, Wang J, Pelletier RP, et al. Key role for CD4 T cells during mixed antibody-mediated rejection of renal allografts. Am J Transplant. 2014;14:284-294.
44. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol. 2007;18:1046-1056.
45. Gloor J, Cosio F, Lager DJ, et al. The spectrumof antibody-mediated renal allograft injury: implications for treatment. Am J Transplant. 2008;8: 1367-1373.
46. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009; 9:2520-2531.
47. Kasi PM, Tawbi HA, Oddis CV, et al. Clinical review: serious adverse events associated with the use of rituximab-a critical care perspective. Crit Care. 2012;16:231.